Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v14-FR | Version v11-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2021-01-26 | 2020-12-13 |
| Drug Identification Number | 02139502 | 02139502 |
| Brand name | VASOPRESSIN INJECTION | VASOPRESSIN INJECTION |
| Common or Proper name | Vasopressin Injection | Vasopressin Injection |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | VASOPRESSIN | VASOPRESSIN |
| Strength(s) | 20UNIT | 20UNIT |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAMUSCULAR SUBCUTANEOUS INTRAMUSCULAR SUBCUTANEOUS | INTRAMUSCULAR SUBCUTANEOUS INTRAMUSCULAR SUBCUTANEOUS |
| Packaging size | 20 units/ mL, MD Vial,1 mL | 20 units/ mL, MD Vial,1 mL |
| ATC code | H01BA | H01BA |
| ATC description | POSTERIOR PITUITARY LOBE HORMONES | POSTERIOR PITUITARY LOBE HORMONES |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | ||
| Actual start date | 2020-08-04 | 2020-08-04 |
| Estimated end date | 2021-01-31 | 2021-01-31 |
| Actual end date | 2021-01-04 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Fresenius Kabi Canada Ltd. regrets to advise that due to manufacturing constraints related to the Active Pharmaceutical Ingredient (API), we will be placing our Vasopressin Injection, 20 units/ mL, 1 mL MD Vials on reduced allocation. Contract customers will be allocated 50% of their historical average monthly volumes, effective August 3, 2020 (UPDATE 09/01/2020) Fresenius Kabi Canada Ltd. regrets to advise that due to manufacturing constraints related to the Active Pharmaceutical Ingredient (API), we will be placing our Vasopressin Injection, 20 units/ mL, MD Vial, 1 mL on reduced allocation. Contract customers will be allocated 25% of their historical average monthly volumes, effective September 1, 2020. UPDATE 12/03: Estimated Availability Date December 21, 2020 UPDATE 12/13: Estimated Availability Date January 2021 (exact date: TBA) UPDATE Fresenius Kabi Canada Ltd. is pleased to advise that replenishment inventories of our Vasopressin Injection 20 units/mL MD Vial 1 mL are expected to be available by January 4, 2021 for the Ontario region and between January 6 – 8, 2021 for all other regions. Fresenius Kabi recognizes the critical need for this product and has been working diligently to resolve the situation and resupply the market as expeditiously as possible. Allocations for Vasopressin Injection will be set at 200% based on historical demand to allow customers to replenish depleted safety stock levels. | Fresenius Kabi Canada Ltd. regrets to advise that due to manufacturing constraints related to the Active Pharmaceutical Ingredient (API), we will be placing our Vasopressin Injection, 20 units/ mL, 1 mL MD Vials on reduced allocation. Contract customers will be allocated 50% of their historical average monthly volumes, effective August 3, 2020 (UPDATE 09/01/2020) Fresenius Kabi Canada Ltd. regrets to advise that due to manufacturing constraints related to the Active Pharmaceutical Ingredient (API), we will be placing our Vasopressin Injection, 20 units/ mL, MD Vial, 1 mL on reduced allocation. Contract customers will be allocated 25% of their historical average monthly volumes, effective September 1, 2020. UPDATE 12/03: Estimated Availability Date December 21, 2020 UPDATE 12/13: Estimated Availability Date January 2021 (exact date: TBA) |
| Health Canada comments |